Immunotherapy in pancreatic cancer:Unleash its potential through novel combinations

查看全文 作　　者：Songchuan [1]Guo;Merly [1]Contratto;George [1]Miller;Lawrence [1]Leichman;Jennifer [1]Wu

机构地区：[1]Division of Hematology and Oncology,Perlmutter Cancer Center,New York University School of Medicine

出　　处：《World Journal of Clinical Oncology》索引2017年第8卷第3期,共11页

摘　　要：Pancreatic cancer is the third leading cause of cancer mortality in both men and women in the United States,with poor response to current standard of care,short progression-free and overall survival.Immunotherapies that target cytotoxic T lymphocyte antigen-4,programmed cell death protein-1,and programmed death-ligand 1 checkpoints have shown remarkable activities in several cancers such as melanoma,renal cell carcinoma,and nonsmall cell lung cancer due to high numbers of somatic mutations,combined with cytotoxic T-cell responses.However,single checkpoint blockade was ineffective in pancreatic cancer,highlighting the challenges including the poor antigenicity,a dense desmoplastic stroma,and a largely immunosuppressive microenvironment.In this review,we will summarize available clinical results and ongoing efforts of combining immune checkpoint therapies with other treatment modalities such as chemotherapy,radiotherapy,and targeted therapy.These combination therapies hold promise in unleashing the potential of immunotherapy in pancreatic cancer to achieve better and more durable clinical responses by enhancing cytotoxic T-cell responses. 关键词：IMMUNOTHERAPY Pancreatic cancer Antiprogrammed CELL DEATH protein-1 Anti-programmed CELL DEATH protein-ligand1 Anti-cytotoxic T lymphocyte antigen-4 Single THERAPY Combination therapies Radiation THERAPY GVAX CRS-207 CD40 agonist

相关文献

参考文献（86）
引证文献（3）
耦合文献（0）

参考文献(86)

引证文献(3)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Immunotherapy in pancreatic cancer:Unleash its potential through novel combinations

参考文献(86)

引证文献(3)

用户提示